Alnylam wins ruling in ongoing legal battle with Tekmira; Metformin offers potential cheap attack on tumors;

Conversations on Twitter :

 @FierceBiotech: Tagging the lows: RNA biomarkers personalize depression treatment. More | Follow @FierceBiotech

 @RyanMFierce: Ouch. Cardiome doesn't have much to fall back on after this Afib program that Merck has dropped back in its lap. More | Follow @RyanMFierce

> The U.S. District Court of the District of Massachusetts denied Tekmira Pharmaceuticals' motion to dismiss some claims and disqualify Alnylam Pharmaceuticals' ($ALNY) counsel in an infringement suit. Release

> The diabetes drug metformin could become an inexpensive treatment for numerous cancers, Bloomberg reports. Article

> Astellas Pharma's potential to win FDA approval for an organ-rejection treatment could cost Veloxis Pharmaceuticals. Item

> Depomed is suing the FDA to get market exclusivity for its pain drug. Article

Pharma News

Did Valeant bid too high for Medicis? Analysts cite flagging scripts for lead drug, Solodyn. More | Follow @FiercePharma

> J&J aimed Risperdal pitch at childrens' doctors, witness says. Story

> Reckitt petitions FDA to force 'child resistant' packaging on Suboxone rivals. Article

> Is Valeant's $2.6B price for Medicis too high? More

Medical Device News

 @FierceMedDev: EU proposes tougher medical device rules in light of breast implant scandal. More | Follow @FierceMedDev

 @DamianFierce: Smith & Nephew has issued a device failure warning for one of its all-metal hip implants. More | Follow @DamianFierce

> Mainstay Medical snags $20M for back pain device. More

> Custom Medical Specialties hit with Class I recall of surgical kits. News

> Stryker unleashes global recall of chest fluid pump device. Article

Biomarkers News

> Marker picks out the right people for stroke therapy. More

> Genes power bowel cancer marker panel. News

> Cutting through the silence of heart disease. Article

Drug Delivery News

> Pulsing nanotubes pump out drugs. Story

> SkyePharma's Flutiform launches in Germany, Kyorin seeks OK in Japan. News

> Boston Scientific's stent opens blood vessels and European markets. Article

And Finally… Ex-Pfizer ($PFE) R&D chief John LaMattina takes on those who question the use of pharmaceuticals in his latest column. Column

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.